Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Introduction: Plasma proteins have been widely studied as candidate biomarkers to predict brain amyloid deposition to increase recruitment efficiency in secondary prevention clinical trials for Alzheimer's disease. Most such biomarker studies are targeted to specific proteins or are biased toward high abundant proteins. Methods: 4001 plasma proteins were measured in two groups of participants (discovery group = 516, replication group = 365) selected from the European Medical Information Framework for Alzheimer's disease Multimodal Biomarker Discovery study, all of whom had measures of amyloid. Results: A panel of proteins (n = 44), along with age and apolipoprotein E (APOE) ε4, predicted brain amyloid deposition with good performance in both the discovery group (area under the curve = 0.78) and the replication group (area under the curve = 0.68). Furthermore, a causal relationship between amyloid and tau was confirmed by Mendelian randomization. Discussion: The results suggest that high‐dimensional plasma protein testing could be a useful and reproducible approach for measuring brain amyloid deposition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bowden, J., Davey Smith, G., & Burgess, S. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv080 · Cited by 9,816 · cited 1×
“The Egger method is sensitive to SNP pleiotropy and allows the estimation of underlying bias by allowing a non-zero estimate for the intercept of the calculated ratio of b values [34].”
A basic introduction to fixed-effect and random-effects models for meta-analysis
Borenstein, M., Hedges, L. V., Higgins, J. P. T., & Rothstein, H. R. (2010) · Research Synthesis Methods · doi:10.1002/jrsm.12 · Cited by 6,793 · cited 1×
“The IVWmethod uses the same ratio estimates but incorporates IVWs into the final summary estimate [36].”
Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models
Ittner, L. M., Ke, Y. D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wölfing, H., Chieng, B. C., Christie, M. J., Napier, I. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.036 · Cited by 1,821
Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery
Gold, L., Ayers, D., Bertino, J., Bock, C., Bock, A., Brody, E. N., Carter, J., Dalby, A. B., Eaton, B. E., Fitzwater, T., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015004 · Cited by 1,754
High performance plasma amyloid-β biomarkers for Alzheimer's disease
Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., et al. (2018) · Nature · doi:10.1038/nature25456 · Cited by 1,681
Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis
Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., Visser, P. J., Aalten, P., Aarsland, D., Alcolea, D., et al. (2015) · JAMA · doi:10.1001/jama.2015.4668 · Cited by 1,610
Self-citationAmyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
Rowe, C. C., Ellis, K. A., Rimajova, M., Bourgeat, P., Pike, K. E., Jones, G., Fripp, J., Tochon-Danguy, H., Morandeau, L., O'Keefe, G., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.007 · Cited by 986
APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging
Morris, J. C., Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., & Mintun, M. A. (2010) · Annals of Neurology · doi:10.1002/ana.21843 · Cited by 830
The case for rejecting the amyloid cascade hypothesis
Herrup, K. (2015) · Nature Neuroscience · doi:10.1038/nn.4017 · Cited by 768
Alzheimer's disease drug development pipeline: 2018
Cummings, J., Lee, G., Ritter, A., & Zhong, K. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.03.009 · Cited by 697 · cited 2×
“Moreover, these findings are potentially useful in clinical trial settings especially as increasing number of clinical trials are directed at tau-related targets [1].”
Cited by
Wang, Y., Sun, Y., Wang, Y., Jia, S., Qiao, Y., Zhou, Z., Shao, W., Zhang, X., Guo, J., Zhang, B., et al. (2023) · Alzheimer's Research & Therapy · doi:10.1186/s13195-023-01324-4 · Cited by 34
“The classifier consisted of feature selection and classifiers [38].”
MethodUsing blood transcriptome analysis for Alzheimer's disease diagnosis and patient stratification
Zhong, H., Zhou, X., Uhm, H., Jiang, Y., Cao, H., Chen, Y., Mak, T. T. W., Lo, R. M. N., Wong, B. W. Y., Cheng, E. Y. L., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13691 · Cited by 25
Thanasupawat, T., Glogowska, A., Pascoe, C., Krishnan, S. N., Munir, M., Begum, F., Beiko, J., Krcek, J., Del Bigio, M. R., Pitz, M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179566 · Cited by 8
Gómez-Pascual, A., Naccache, T., Xu, J., Hooshmand, K., Wretlind, A., Gabrielli, M., Lombardo, M. T., Shi, L., Buckley, N. J., Tijms, B. M., et al. (2023) · doi:10.1101/2023.03.02.23286674 · Cited by 1
Self-citation
Metadata
- Authors
- Shi, L., Westwood, S., Baird, A. L., Winchester, L., Dobricic, V., Kilpert, F., Hong, S., Franke, A., Hye, A., Ashton, N. J., Morgan, A. R., Bos, I., Vos, S. J. B., Buckley, N. J., Kate, M. T., Scheltens, P., Vandenberghe, R., Gabel, S., Meersmans, K., Engelborghs, S., De Roeck, E. E., Sleegers, K., Frisoni, G. B., Blin, O., Richardson, J. C., Bordet, R., Molinuevo, J. L., Rami, L., Wallin, A., Kettunen, P., Tsolaki, M., Verhey, F., Lleó, A., Alcolea, D., Popp, J., Peyratout, G., Martinez‐Lage, P., Tainta, M., Johannsen, P., Teunissen, C. E., Freund‐Levi, Y., Frölich, L., Legido‐Quigley, C., Barkhof, F., Blennow, K., Zetterberg, H., Baker, S., Morgan, B. P., Streffer, J., Visser, P. J., Bertram, L., Lovestone, S., & Nevado‐Holgado, A. J.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2019-09-05
- Volume
- 15
- Issue
- 11
- Pages
- 1478-1488
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2971816621
- Cited by
- 74
- References
- 25
- FWCI
- 7.20
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. https://app.cochat.ai/papers/10.1016/j.jalz.2019.06.4951
- The paper
- Shi, L., Westwood, S., Baird, A. L., Winchester, L., Dobricic, V., Kilpert, F., Hong, S., Franke, A., Hye, A., Ashton, N. J., Morgan, A. R., Bos, I., Vos, S. J. B., Buckley, N. J., Kate, M. T., Scheltens, P., Vandenberghe, R., Gabel, S., Meersmans, K., . . . Nevado‐Holgado, A. J. (2019). Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2019.06.4951
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.